TabletsClinical Overview
Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Asthma and/or allergic rhinitis: Take orally once daily in the evening with a glass of water, with or without food (10 mg for adults; 5 mg for children 6-14 years). Exercise-induced bronchospasm: Take 10 mg at least 2 hours before exercise. NOT for reversal of acute bronchospasm.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Upper respiratory tract infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea. Rare/Severe: Neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal ideation), systemic eosinophilia and Churg-Strauss syndrome, and hepatotoxicity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Serious neuropsychiatric events (suicidal thoughts and actions, depression, aggression, sleep disturbances); discontinue immediately and seek medical attention if mood or behavioral changes occur. Not a rescue medication for acute asthma attacks; patients must continue rescue inhalers.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Montelukast Sodium Tablets 5mg
Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.
Montelukast Sodium 10mg + Levocetirizine 5mg Tablets
Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.
Montelukast Sodium 10mg + Fexofenadine Hydrochloride 120 mg Tablets
Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.
Acebrophylline 200mg (Sustained Release) + Montelukast 10mg Tablets
Acebrophylline Capsules / Tablets (100mg, 200mg Sustained Release; alone or with Montelukast 10mg or Acetylcysteine 600mg) is a fixed salt of ambroxol and theophylline-7-acetic acid on the PMBI formulary. It exerts a triple therapeutic action: potent bronchodilation via phosphodiesterase inhibition; mucoregulatory and surfactant-stimulating action via ambroxol (stimulating alveolar type II pneumocytes to produce pulmonary surfactant, reducing mucus viscosity and improving mucociliary clearance); and anti-inflammatory inhibition of phospholipase A2 and leukotriene C4. Indicated for bronchial asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic spastic bronchitis with thick viscid sputum.